keyboard_arrow_up

Molecular Diagnostics Partnering Terms and Agreements

Molecular Diagnostics Partnering Terms and Agreements is a new market research publication announced by Reportstack. This report provides a detailed understanding and analysis of how and why companies enter molecular diagnostics partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.  This report provides details of the latest molecular diagnostics agreements announced in the healthcare sectors.
 
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not. 
 
This report contains a comprehensive listing of all molecular diagnostics partnering deals announced since 2009 including financial terms where available including over 300 links to online deal records of actual molecular diagnostics partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of drug dealmaking and business activities, provides an introduction to the report, an overview of the trends in molecular diagnostics dealmaking since 2009, including details of average headline, upfront, milestone and royalty terms.
                    
This report provides a review of the leading molecular diagnostics deals since 2009. Deals are listed by headline value, signed by big pharma, big biotech, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract, provides a comprehensive listing of the top 50 big pharma companies with a brief summary followed by a comprehensive listing of molecular diagnostics deals, as well as contract documents available in the public domain. 
 
This report provides a comprehensive listing of the top 50 big biotech companies with a brief summary followed by a comprehensive listing of molecular diagnostics deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand, provides a comprehensive and detailed review of molecular diagnostics partnering deals signed and announced since 2009, where a contract document is available in the public domain. The chapter is organized by stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), specific therapy focus and specific technology type. 
 
In addition, a comprehensive appendix is provided organized by molecular diagnostics partnering company A-Z , deal type definitions and molecular diagnostics partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
                                                  
In conclusion, this report provides everything a prospective dealmaker needs to know about molecular diagnostics partnering in the research, development and commercialization of molecular diagnostics technologies and products.
 
Report scope
Molecular Diagnostics Partnering Agreements is intended to provide the reader with an in-depth understanding and access to molecular diagnostics trends and structure of deals entered into by leading companies worldwide.
                                             
Molecular Diagnostics Partnering Agreements includes:
                                                        
Trends in molecular diagnostics dealmaking in the biopharma industry since 2009
Analysis of molecular diagnostics deal structure
Access to headline, upfront, milestone and royalty data
Access to over 300 molecular diagnostics deal records
The leading molecular diagnostics deals by value since 2009  

Molecular Diagnostics Partnering Terms and Agreements provides the reader with the following key benefits:

 
In-depth understanding of molecular diagnostics deal trends since 2009
Access molecular diagnostics deal headline, upfront, milestone and royalty data
Analysis of the structure of molecular diagnostics agreements with numerous real life case studies
Comprehensive access to over 300 links to actual infectious vaccines deals entered into by the world’s biopharma companies, together with real world clause examples
Identify leading molecular diagnostics deals by value since 2009
Identify the most active molecular diagnostics dealmakers since 2009
Insight into the terms included in molecular diagnostics agreement, together with real world clause examples
Understand the key deal terms companies have agreed in previous deals          
Undertake due diligence to assess suitability of your proposed deal terms for partner companies

To access full report with TOC, please visit Molecular Diagnostics Partnering Terms and Agreements.